問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
張獻崑
下載
2021-04-01 - 2033-02-28
Condition/Disease
Test Drug
Participate Sites5Sites
Recruiting5Sites
2020-12-01 - 2025-12-31
2022-06-16 - 2026-06-30
Participate Sites7Sites
Recruiting7Sites
2021-07-01 - 2025-12-31
Participate Sites4Sites
Recruiting4Sites
2020-01-01 - 2029-12-31
Not yet recruiting1Sites
Recruiting6Sites
2022-12-15 - 2027-12-31
2021-11-01 - 2027-03-20
2020-10-15 - 2027-09-01
Participate Sites13Sites
Recruiting13Sites
2014-05-01 - 2029-12-31
Participate Sites6Sites
2017-08-10 - 2025-01-09
Patients with unresectable, previously untreated advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Injection Injection
Participate Sites12Sites
Recruiting12Sites
全部
